Glaucoma Device at AAO

Seeing Machines Limited
08 November 2007



8 November 2007


                            Seeing Machines Limited

                      ('Seeing Machines' or the 'Company')


                       TRUEFIELD ANALYZER PROMOTED AT AAO



Seeing Machines (AIM: SEE), a leading developer of advanced computer based
imaging software systems, announces today that the Company will be promoting the
 TrueField Analyzer(R) at the American Academy of Ophthalmology (AAO) Annual
Meeting in New Orleans from November 10-13 2007.  The TrueField Analyzer(R) is
the Company's revolutionary new medical device to assist doctors in detecting
and managing glaucoma and other eye diseases.

The AAO Annual Meeting is the largest annual event for ophthalmologists with
over 30,000 attendees and 500 exhibiting companies and the perfect event to
showcase the TrueField Analyzer(R)  It is also the first event the Company is
attending to promote the TrueField Analyzer(R) since the United States Food and
Drug Administration (FDA) granted marketing clearance for the TrueField Analyzer
(R) in August 2007.

Further information about the TrueField Analyzer(R) can be obtained from the
website: www.truefield-analyzer.com. Further information about Seeing Machines
can be obtained from the company website www.seeingmachines.com.



--- ENDS ---





Enquiries:


Seeing Machines Limited            Insinger de Beaufort            Parkgreen Communications
Nick Cerneaz, CEO                  Peter Ward, Chris Caldwell      Justine Howarth, Erica Nelson
[phone]                [phone]            [phone]
www.seeingmachines.com



Notes to editors:



About Seeing Machines



Seeing Machines is an award winning Technology Company which focuses on vision
based human machine interfaces.  Formed in 2000 in Canberra, Australia, Seeing
Machines' purpose is to commercialise its computer-vision across a range of
industries and applications.

Seeing Machines deliver advanced computer vision solutions for researches and
developers in human factors, transportation safety, computer human interaction,
robotics, medical research and psychology.  The flagship product faceLAB(R)
provides an automated and contact-free gaze and head tracking technology, it
solves the problem of observing human behaviour naturally, non-intrusively and
with a high degree of accuracy and usability.  Building on these unique face
tracking and pupil measurement and monitoring capabilities, the TrueField
Analyzer(R) is new medical device to assist clinicians detect and manage eye
diseases such as glaucoma.

The TrueField Analyzer(R) offers a new objective method to help doctors diagnose
and manage a range of eye diseases including glaucoma, age related macular
degeneration and diabetic retinopathy.   Glaucoma affects about 2-3% of the
population over 40 years of age and is a leading source of blindness.   Unlike
most other devices available to the clinician the TrueField Analyzer is a
completely objective test and it is quick and easy for patients and technicians
alike.  The device measures both eyes concurrently and due to the reliability
that arises from the objective nature of the test, it has the potential to
become a new standard in the measurement of visual field defects and thus in the
diagnosis and management of disease such as glaucoma.

More generally Seeing Machines' computer vision systems are able to measure the
orientation and position of a human head, estimate eye-gaze direction, detect
eye blinks and track other facial features. This functionality is achieved
entirely though visual means, using video cameras connected to advanced image
processing software, with no attachments required on the subject.  Products such
as faceLAB(R) are designed to allow human factors researchers and designers to
assess the interaction of an operator in an environment and this finds
application in designing operator environments, such as cockpits for cars,
trucks, trains, and aeroplanes for instance, and other industrial design
applications, as well as medical and psychological research situations.  The
technology has been developed into the Driver State Sensor (DSS2) product for
application in monitoring vehicle drivers and if it detects drowsiness (fatigue)
or that the driver is distracted and their attention has been diverted from the
road, alarms are raised to alert the driver to these events.  In larger
deployments, such as in fleet and mining equipment operations, the data is
available in both real-time and off-line modes for fleet management, driver
training and awareness programs

The systems work in real-time, enabling the behaviour of subjects to be tracked
in real-time.  This technology is paving the way in promoting safer driving
conditions and works to enhance the driving experience and to eliminate
accidents caused through driver drowsiness or distraction.

There are many different sectors that can benefit from this revolutionary
software, for which it has been developed, including: automotive; academic
research; medicine/healthcare; defence; autostereoscopy (next generation
displays); sport; and games.


                      This information is provided by RNS
            The company news service from the London Stock Exchange